BR112014015142A2 - di-hidropirimidinoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de distúrbios inflamatórios - Google Patents

di-hidropirimidinoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de distúrbios inflamatórios

Info

Publication number
BR112014015142A2
BR112014015142A2 BR112014015142A BR112014015142A BR112014015142A2 BR 112014015142 A2 BR112014015142 A2 BR 112014015142A2 BR 112014015142 A BR112014015142 A BR 112014015142A BR 112014015142 A BR112014015142 A BR 112014015142A BR 112014015142 A2 BR112014015142 A2 BR 112014015142A2
Authority
BR
Brazil
Prior art keywords
treatment
pharmaceutical compositions
dihydropyrimidinoisoquinolinones
diseases
pulmonary disease
Prior art date
Application number
BR112014015142A
Other languages
English (en)
Other versions
BR112014015142B1 (pt
Inventor
Gilbert Labéguère Frédéric
John Robert Newsome Gregory
Raymond Maurice Sanière Laurent
Jonathan Alvey Luke
Robert Fletcher Stephen
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of BR112014015142A2 publication Critical patent/BR112014015142A2/pt
Publication of BR112014015142B1 publication Critical patent/BR112014015142B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

resumo patente de invenção: "di-hidropirimidinoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de distúrbios inflamatórios". a presente invenção refere-se a um composto de acordo com a fórmula (ia): em que l1, g, e r1 são como descrito aqui. a presente invenção refere-se a novos compostos de acordo com a fórmula (i) que antagonizam gpr84, um receptor acoplado à proteína g que está envolvido em condições inflamatórias, e métodos para a produção destes novos compostos, composições farmacêuticas compreendendo estes compostos, e métodos para a prevenção e/ou tratamento de condições inflamatórias (por exemplo, doenças do intestino inflamatório (ibd), artrite reumatoide, vasculite, doenças pulmonares (por exemplo, doença pulmonar obstrutiva crônica (copd) e doenças intersticiais pulmonares (por exemplo, fibrose pulmonar idiopática (ipf))), condições neuroinflamatórias, doenças infecciosas, doenças autoimunes, doenças endócrinas e/ou metabólicas, e/ou doenças envolvendo dano de funções de célula imune administrando um composto da invenção. 21604626v1 1/1 21604626v1
BR112014015142-3A 2011-12-22 2012-12-20 Di-hidropirimidinoisoquinolinonas, seus usos, e composição farmacêutica BR112014015142B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578979P 2011-12-22 2011-12-22
US61/578,979 2011-12-22
PCT/EP2012/076275 WO2013092791A1 (en) 2011-12-22 2012-12-20 Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
BR112014015142A2 true BR112014015142A2 (pt) 2017-06-13
BR112014015142B1 BR112014015142B1 (pt) 2022-03-29

Family

ID=47520068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014015142-3A BR112014015142B1 (pt) 2011-12-22 2012-12-20 Di-hidropirimidinoisoquinolinonas, seus usos, e composição farmacêutica

Country Status (35)

Country Link
US (5) US8927543B2 (pt)
EP (3) EP3378862B1 (pt)
JP (1) JP6062453B2 (pt)
KR (1) KR102012268B1 (pt)
CN (1) CN103998448B (pt)
AR (1) AR089284A1 (pt)
AU (1) AU2012357067B2 (pt)
BR (1) BR112014015142B1 (pt)
CA (1) CA2859578C (pt)
CL (1) CL2014001664A1 (pt)
CO (1) CO7010835A2 (pt)
CR (1) CR20140305A (pt)
CY (1) CY1119434T1 (pt)
DK (2) DK3378862T3 (pt)
EA (1) EA023826B1 (pt)
ES (2) ES2643379T3 (pt)
HK (1) HK1201528A1 (pt)
HR (2) HRP20220456T1 (pt)
HU (1) HUE12812237T4 (pt)
IL (2) IL233212B (pt)
IN (1) IN2014MN01033A (pt)
LT (2) LT3378862T (pt)
MX (1) MX351681B (pt)
NI (1) NI201400060A (pt)
PE (1) PE20141685A1 (pt)
PH (1) PH12014501178B1 (pt)
PL (2) PL2794604T3 (pt)
PT (2) PT2794604T (pt)
SG (1) SG11201403169PA (pt)
SI (2) SI2794604T1 (pt)
TW (1) TWI567073B (pt)
UA (1) UA111767C2 (pt)
UY (1) UY34545A (pt)
WO (1) WO2013092791A1 (pt)
ZA (1) ZA201404607B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107459544B (zh) 2011-12-22 2021-03-16 詹森生物制药有限公司 取代的核苷、核苷酸及其类似物
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN104870445B (zh) * 2012-12-20 2017-09-15 加拉帕戈斯股份有限公司 用于治疗炎性疾病的新二氢嘧啶并异喹啉酮类及其药物组合物(gpr84拮抗剂)
GB201319677D0 (en) * 2013-11-07 2013-12-25 Eth Z Rich Cyclopropanation
GB201411241D0 (en) * 2014-06-25 2014-08-06 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201506894D0 (en) * 2015-04-23 2015-06-10 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US11098071B2 (en) 2017-03-06 2021-08-24 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences GPR84 receptor antagonist and use thereof
EP3403649A1 (en) 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
KR20200088844A (ko) 2017-11-15 2020-07-23 갈라파고스 엔.브이. 섬유증성 질병 치료에서의 용도를 위한 화합물 및 그의 약학 조성물
BR112022011237A2 (pt) 2019-12-19 2022-08-30 Bayer Ag Derivados de furoindazol
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
WO2022112186A1 (en) 2020-11-24 2022-06-02 Galapagos Nv Compound for use in and methods of treatment of fibrotic diseases
EP4298102A1 (en) * 2021-02-23 2024-01-03 Bayer Aktiengesellschaft Furoindazole derivatives as gpr84 antagonists
CN115109072A (zh) * 2021-03-18 2022-09-27 武汉人福创新药物研发中心有限公司 一种gpr84拮抗剂及其制备方法和用途
WO2022218372A1 (zh) * 2021-04-14 2022-10-20 武汉人福创新药物研发中心有限公司 一种二氢嘧啶并异喹啉酮类衍生物及用途
US20240239804A1 (en) 2021-04-29 2024-07-18 Bayer Aktiengesellschaft Furoindazole derivatives as antagonists or inhibitors of gpr84
EP4355743A1 (en) 2021-06-18 2024-04-24 University of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
EP4361151A1 (en) 2021-06-21 2024-05-01 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Tricyclic compound used as gpr84 antagonist
CN115611944A (zh) 2021-07-15 2023-01-17 中国科学院上海药物研究所 不对称gpr84拮抗剂及其用途
WO2023076668A1 (en) * 2021-10-29 2023-05-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treatment of cancer
WO2024083705A1 (en) 2022-10-18 2024-04-25 Bayer Aktiengesellschaft Furoindazole derivatives for the treatment of pain
WO2024140969A1 (zh) * 2022-12-30 2024-07-04 广州市联瑞制药有限公司 三环类化合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2720085A1 (de) 1977-05-05 1978-11-16 Hoechst Ag Pyrimido(6,1-a)isochinolin-2-on- derivate
WO1999002162A1 (en) * 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
BR0009449A (pt) * 1999-03-31 2002-01-08 Vernalis Ltd Composto, processo para preparar um composto, composição, uso de um composto, e, métodos para o tratamento ou prevenção de uma doença em um mamìfero onde deve-se esperar que um inibidor da isoenzima de fosfodiesterase e/ou um broncodilatador sejam benéficos, para o tratamento ou prevenção da asma em um mamìfero e para o tratamento ou prevenção da doença pulmonar obstrutiva crÈnica (copd) em um mamìfero
EP1641766A2 (en) * 2003-07-08 2006-04-05 Smithkline Beecham Corporation Novel chemical compounds
WO2005050225A2 (en) 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
AU2006284926A1 (en) 2005-09-02 2007-03-08 Arena Pharmaceuticals, Inc. Human G protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to MCP-1 expression
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
WO2010014939A1 (en) 2008-07-31 2010-02-04 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
PL2794600T3 (pl) 2011-12-22 2018-06-29 Novartis Ag Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
EP2800748B1 (en) 2011-12-22 2017-03-29 Connexios Life Sciences Pvt. Ltd. Cyclic amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase and uses thereof
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
US9303016B2 (en) 2011-12-22 2016-04-05 Connexios Life Sciences Pvt. Ltd. Derivatives of aza adamantane and uses thereof
CN104870445B (zh) 2012-12-20 2017-09-15 加拉帕戈斯股份有限公司 用于治疗炎性疾病的新二氢嘧啶并异喹啉酮类及其药物组合物(gpr84拮抗剂)

Also Published As

Publication number Publication date
PT2794604T (pt) 2017-10-23
JP2015500861A (ja) 2015-01-08
TWI567073B (zh) 2017-01-21
PE20141685A1 (es) 2014-11-25
SG11201403169PA (en) 2014-07-30
US11220499B2 (en) 2022-01-11
HRP20220456T1 (hr) 2022-05-27
IN2014MN01033A (pt) 2015-05-01
NZ626473A (en) 2016-03-31
LT2794604T (lt) 2017-10-25
SI2794604T1 (sl) 2017-12-29
EA023826B1 (ru) 2016-07-29
US20130165437A1 (en) 2013-06-27
SI3378862T1 (sl) 2022-05-31
UY34545A (es) 2013-07-31
NI201400060A (es) 2015-04-27
US8927543B2 (en) 2015-01-06
IL257581A (en) 2018-04-30
US10047083B2 (en) 2018-08-14
HUE12812237T4 (hu) 2017-12-28
TW201331201A (zh) 2013-08-01
ES2643379T9 (es) 2018-01-05
PL3378862T3 (pl) 2022-05-16
EP2794604A1 (en) 2014-10-29
IL233212A0 (en) 2014-08-31
UA111767C2 (uk) 2016-06-10
IL233212B (en) 2018-03-29
CN103998448B (zh) 2016-04-20
EP4019519A1 (en) 2022-06-29
PH12014501178A1 (en) 2014-10-20
CY1119434T1 (el) 2018-03-07
US20190002458A1 (en) 2019-01-03
ZA201404607B (en) 2020-02-26
CA2859578C (en) 2020-03-10
LT3378862T (lt) 2022-04-25
HK1201528A1 (en) 2015-09-04
CA2859578A1 (en) 2013-06-27
CR20140305A (es) 2014-07-23
KR102012268B1 (ko) 2019-08-21
CN103998448A (zh) 2014-08-20
WO2013092791A1 (en) 2013-06-27
EP2794604B1 (en) 2017-09-13
US20220227751A1 (en) 2022-07-21
ES2911449T3 (es) 2022-05-19
US20140121204A1 (en) 2014-05-01
US9255095B2 (en) 2016-02-09
CO7010835A2 (es) 2014-07-31
AU2012357067A1 (en) 2014-07-10
BR112014015142B1 (pt) 2022-03-29
EA201491245A1 (ru) 2014-10-30
US20160244442A1 (en) 2016-08-25
DK3378862T3 (da) 2022-04-11
CL2014001664A1 (es) 2014-10-03
HRP20171404T1 (hr) 2017-11-17
MX351681B (es) 2017-10-25
PL2794604T3 (pl) 2017-12-29
EP3378862B1 (en) 2022-03-16
JP6062453B2 (ja) 2017-01-18
PH12014501178B1 (en) 2014-10-20
PT3378862T (pt) 2022-04-11
AR089284A1 (es) 2014-08-13
AU2012357067B2 (en) 2017-01-05
KR20140117427A (ko) 2014-10-07
ES2643379T3 (es) 2017-11-22
EP3378862A1 (en) 2018-09-26
DK2794604T3 (da) 2017-11-06
MX2014007363A (es) 2014-08-01

Similar Documents

Publication Publication Date Title
BR112014015142A2 (pt) di-hidropirimidinoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de distúrbios inflamatórios
BR112017022008A2 (pt) composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios
AR126555A2 (es) Anticuerpos de oncostatina m humana y métodos de uso
BR112014006271A2 (pt) composições farmacêuticas
IN2014DN09352A (pt)
IN2014DN09348A (pt)
IN2014MN01839A (pt)
MX355742B (es) Análogos deuterados del ácido 4-hidroxibutírico.
PE20190440A1 (es) Anticuerpos a la alfa-sinucleina y usos de los mismos
JP2015517489A5 (pt)
JP2014527040A5 (pt)
MX2019015350A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de la fibrosis.
CO2021017031A2 (es) Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3)
IN2014DN07885A (pt)
EA201492283A1 (ru) Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
CO2022008338A2 (es) Derivados de furoindazol
EA201491206A1 (ru) Ингаляционное лекарственное средство, содержащее тиотропий
AR087168A1 (es) Compuesto derivado de pirimidina sulfonamida
WO2011158110A3 (en) Cilostazol cocrystals and compositions
AR089860A1 (es) Analogos de la grelina
IN2014CN02332A (pt)
EA201491238A1 (ru) Новая фармацевтическая композиция флурбипрофена и глюкозамина
MX2021014116A (es) Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
BR112014000485A2 (pt) derivados de azetidina para o tratamento de transtornos relacionados à melanina
PH12015502560A1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.1 NA RPI NO 2653 DE 09/11/2021 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2012, OBSERVADAS AS CONDICOES LEGAIS.